AIMS: Lung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak.METHODS: Fifteen molecular laboratories from seven different European countries compared 4weeks of national lockdown to a corresponding period in 2019, in terms of tissue and/or plasma-based molecular test workload, analytical platforms adopted, number of cases undergoing programmed death-ligand1 (PD-L1) expression assessment and DNA-based molecular tests turnaround time.RESULTS: In most laboratories (80.0%), tissue-based molecular test workload was reduced. In 40.0% of laboratories (6/15), the decrease was >25%, and in one, reduction was as high as 80.0%. In this instance, a concomitant increase in liquid biopsy was reported (60.0%). Remarkably, in 33.3% of the laboratories, real-time PCR (RT-PCR)-based methodologies increased, whereas highly multiplexing assays approaches decreased. Most laboratories (88.9%) did not report significant variations in PD-L1 volume testing.CONCLUSIONS: The workload of molecular testing for patients with advanced-stage lung cancer during the lockdown showed little variations. Local strategies to overcome health emergency-related issues included the preference for RT-PCR tissue-based testing methodologies and, occasionally, for liquid biopsy.

Malapelle, U., Pisapia, P., Iaccarino, A., Barberis, M., Bellevicine, C., Brunnström, H., et al. (2021). Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. JOURNAL OF CLINICAL PATHOLOGY, 74, 391-395 [10.1136/jclinpath-2020-206957].

Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe

de Biase, Dario;Tallini, Giovanni;
2021

Abstract

AIMS: Lung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak.METHODS: Fifteen molecular laboratories from seven different European countries compared 4weeks of national lockdown to a corresponding period in 2019, in terms of tissue and/or plasma-based molecular test workload, analytical platforms adopted, number of cases undergoing programmed death-ligand1 (PD-L1) expression assessment and DNA-based molecular tests turnaround time.RESULTS: In most laboratories (80.0%), tissue-based molecular test workload was reduced. In 40.0% of laboratories (6/15), the decrease was >25%, and in one, reduction was as high as 80.0%. In this instance, a concomitant increase in liquid biopsy was reported (60.0%). Remarkably, in 33.3% of the laboratories, real-time PCR (RT-PCR)-based methodologies increased, whereas highly multiplexing assays approaches decreased. Most laboratories (88.9%) did not report significant variations in PD-L1 volume testing.CONCLUSIONS: The workload of molecular testing for patients with advanced-stage lung cancer during the lockdown showed little variations. Local strategies to overcome health emergency-related issues included the preference for RT-PCR tissue-based testing methodologies and, occasionally, for liquid biopsy.
2021
Malapelle, U., Pisapia, P., Iaccarino, A., Barberis, M., Bellevicine, C., Brunnström, H., et al. (2021). Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. JOURNAL OF CLINICAL PATHOLOGY, 74, 391-395 [10.1136/jclinpath-2020-206957].
Malapelle, Umberto; Pisapia, Pasquale; Iaccarino, Antonino; Barberis, Massimo; Bellevicine, Claudio; Brunnström, Hans; de Biase, Dario; De Maglio, Gio...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/803412
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 14
social impact